225 related articles for article (PubMed ID: 28481080)
1. Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Johansen ML; Gao Y; Hutnick MA; Craig SEL; Pokorski JK; Flask CA; Brady-Kalnay SM
Anal Chem; 2017 Jun; 89(11):5932-5939. PubMed ID: 28481080
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of Tumors Using a Quantitative T 1 Mapping Technique via Magnetic Resonance Imaging.
Herrmann K; Johansen ML; Craig SE; Vincent J; Howell M; Gao Y; Lu L; Erokwu B; Agnes RS; Lu ZR; Pokorski JK; Basilion J; Gulani V; Griswold M; Flask C; Brady-Kalnay SM
Diagnostics (Basel); 2015; 5(3):318-32. PubMed ID: 26435847
[TBL] [Abstract][Full Text] [Related]
3. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
[TBL] [Abstract][Full Text] [Related]
4. Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging.
Li Y; Liu G; Lou X; Chen Z; Ma L
Sci China Life Sci; 2017 Jan; 60(1):11-15. PubMed ID: 28078511
[TBL] [Abstract][Full Text] [Related]
5. Combined molecular MRI and immuno-spin-trapping for in vivo detection of free radicals in orthotopic mouse GL261 gliomas.
Towner RA; Smith N; Saunders D; De Souza PC; Henry L; Lupu F; Silasi-Mansat R; Ehrenshaft M; Mason RP; Gomez-Mejiba SE; Ramirez DC
Biochim Biophys Acta; 2013 Dec; 1832(12):2153-61. PubMed ID: 23959048
[TBL] [Abstract][Full Text] [Related]
6. Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents.
Johansen ML; Perera R; Abenojar E; Wang X; Vincent J; Exner AA; Brady-Kalnay SM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671448
[TBL] [Abstract][Full Text] [Related]
7. MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.
Liu X; Madhankumar AB; Miller PA; Duck KA; Hafenstein S; Rizk E; Slagle-Webb B; Sheehan JM; Connor JR; Yang QX
Neuro Oncol; 2016 May; 18(5):691-9. PubMed ID: 26519740
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Gd(DO3A-Lys) and MR imaging studies in an orthotopic U87MG glioma tumor model.
Chandrasekharan P; Yang CT; Nasrallah FA; Tay HC; Chuang KH; Robins EG
Contrast Media Mol Imaging; 2015; 10(3):237-44. PubMed ID: 25612157
[TBL] [Abstract][Full Text] [Related]
9. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
Caravan P
Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
[TBL] [Abstract][Full Text] [Related]
10. Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.
Zhou Z; Wu X; Kresak A; Griswold M; Lu ZR
Biomaterials; 2013 Oct; 34(31):7683-93. PubMed ID: 23863450
[TBL] [Abstract][Full Text] [Related]
11. Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection.
Bagga P; Haris M; D'Aquilla K; Wilson NE; Marincola FM; Schnall MD; Hariharan H; Reddy R
J Transl Med; 2017 May; 15(1):119. PubMed ID: 28558795
[TBL] [Abstract][Full Text] [Related]
12. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging of angiogenesis to delineate the tumor margins in glioma rat model with endoglin-targeted paramagnetic liposomes using 3T MRI.
Qiu LH; Zhang JW; Li SP; Xie C; Yao ZW; Feng XY
J Magn Reson Imaging; 2015 Apr; 41(4):1056-64. PubMed ID: 24677456
[TBL] [Abstract][Full Text] [Related]
14. Anti-EpCAM scFv gadolinium chelate: a novel targeted MRI contrast agent for imaging of colorectal cancer.
Khantasup K; Saiviroonporn P; Jarussophon S; Chantima W; Dharakul T
MAGMA; 2018 Oct; 31(5):633-644. PubMed ID: 29737435
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs.
Zhang RR; Choi C; Brunnquell CL; Hernandez R; Pinchuk AN; Grudzinski JG; Clark PA; McMillan AB; Audhya A; Jeffrey J; Kuo JS; Weichert JP
Invest Radiol; 2022 Oct; 57(10):655-663. PubMed ID: 36069439
[TBL] [Abstract][Full Text] [Related]
16. Connexin 43-targeted T1 contrast agent for MRI diagnosis of glioma.
Abakumova T; Abakumov M; Shein S; Chelushkin P; Bychkov D; Mukhin V; Yusubalieva G; Grinenko N; Kabanov A; Nukolova N; Chekhonin V
Contrast Media Mol Imaging; 2016; 11(1):15-23. PubMed ID: 26265140
[TBL] [Abstract][Full Text] [Related]
17. Development of Bifunctional Gadolinium-Labeled Superparamagnetic Nanoparticles (Gd-MnMEIO) for In Vivo MR Imaging of the Liver in an Animal Model.
Kuo YT; Chen CY; Liu GC; Wang YM
PLoS One; 2016; 11(2):e0148695. PubMed ID: 26886558
[TBL] [Abstract][Full Text] [Related]
18. Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.
Pais A; Biton IE; Margalit R; Degani H
Magn Reson Med; 2013 Jul; 70(1):193-206. PubMed ID: 22887470
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
[TBL] [Abstract][Full Text] [Related]
20. Sensitive MRI detection of internalized T1 contrast agents using magnetization transfer contrast.
Delli Castelli D; Ferrauto G; Di Gregorio E; Terreno E; Aime S
NMR Biomed; 2015 Dec; 28(12):1663-70. PubMed ID: 26474109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
